Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$-0.75
EPS est.
$-0.66
EPS surprise
-14.33%
1-day move
+1.17%
Immunovant's earnings report showed a larger-than-expected loss per share, but the stock still rose by 1.17%. This increase likely reflects investor optimism about the upcoming launch of brepocitinib and the company's strong cash reserves. The management's focus on a careful commercial strategy may also have reassured investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.75 | $-0.73 | -14.33% |
| Revenue | $0M | $0M | N/A |
| R&D Expenses | $200M | N/A | N/A |
| Cash Reserves | $4B | N/A | N/A |
Management expressed cautious optimism about upcoming product launches and data readouts. They emphasized a slow and steady approach to commercialization.
We are preparing for a busy second half of 2026 with multiple late-stage data readouts.
Brepocitinib has shown promising data in phase II studies.
Immunovant, Inc. is a biotechnology company focused on developing therapies for autoimmune diseases. With a market cap of $9 billion, its innovations could significantly impact patient care in the health care sector.
Last quarter
In Q4-2026, Immunovant reported an EPS of $-0.73, missing estimates by a significant margin. Despite this, the stock surged by over 35% the following day, indicating strong investor interest.
EPS beat streak
0Q
EPS beat rate
38%
Avg EPS surprise
-3.69%
Avg 1-day reaction
+4.47%
Analysts expect another loss this quarter, with EPS projected at $-0.73. Investors will be keen to see if the company can provide any positive updates or surprises.
Bull case
If Immunovant can beat EPS estimates and provide encouraging guidance, it could lead to a substantial rally in the stock price, similar to previous quarters.
Bear case
Conversely, if the company fails to meet expectations again, it may lead to a sharp decline in stock price, particularly given the high implied volatility.
Key metrics to watch
EPS
$-0.73Earnings per share is a key indicator of profitability and investor sentiment.
Revenue
$0MAlthough no revenue is expected this quarter, any updates on future revenue streams could influence investor confidence.
The print will turn on these.
Q1
Will the EPS come in better than the consensus estimate of $-0.73?
A beat could signal improving fundamentals and boost investor confidence.
Q2
What updates can management provide regarding future revenue streams?
Insights into future revenue potential could significantly impact stock performance.
—
Est. EPS
$3.08
Est. Rev
$7.2B
Impl. Move
±4.0%
Why consensus could be wrong
The Street is overly focused on the EPS loss and not considering potential positive developments in Immunovant's pipeline that could lead to future revenue.
Supporting evidence
The stock has shown resilience in the past despite EPS misses, suggesting investor optimism.
Options pricing indicates a higher expected move, which could reflect underlying positive sentiment not captured in the consensus.
Key risk
If management provides strong guidance or updates on pipeline progress, it could challenge the current negative sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it could either reinforce or undermine investor confidence in Immunovant's growth potential.
Bull confirmed if
An EPS of better than $-0.73 could confirm a positive trend and investor sentiment.
Bear confirmed if
An EPS worse than $-0.76 would likely confirm ongoing challenges for the company.
What the market is pricing for the move.
Implied Move
±29.13%
Historical Avg
±9.2%
The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±29.1% while IMVT has averaged ±9.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
100.4%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$223,070.22
6,352 sh
2 insiders
Net
$223,070.22
Net selling
Most Active Insiders· 2 open-market trades
$119,589.66
Net selling
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Immunovant beats expectations, history suggests a potential stock increase of around 4.5%, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss could lead to a decline, with historical data suggesting an average drop of around 5.06%.
The lines on the call that would change the story.
$103,480.56
Net selling
Recent Transactions
Oct 2, 2026 · @ $34.11
3,506 sh
$119,589.66
Sep 23, 2026 · @ $36.36
2,846 sh
$103,480.56
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.